American Association for Cancer Research
Browse

sorry, we can't preview this file

ccr-22-3930_supplementary_figure_s8_suppfs8.pptx (305.65 kB)

Supplementary Figure S8 from Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer

Download (305.65 kB)
figure
posted on 2023-08-08, 13:01 authored by Harshabad Singh, Rachel B. Keller, Kevin S. Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan, Elizabeth F. Cohen, Michael Tolstorukov, Elizabeth Andrews, Lauren K. Brais, Annacarolina da Silva, Kimberly Perez, Douglas A. Rubinson, Rishi Surana, Marios Giannakis, Kimmie Ng, Thomas E. Clancy, Matthew B. Yurgelun, Benjamin L. Schlechter, Jeffrey W. Clark, Geoffrey I. Shapiro, Michael H. Rosenthal, Jason L. Hornick, Valentina Nardi, Yvonne Y. Li, Hersh Gupta, Andrew D. Cherniack, Matthew Meyerson, James M. Cleary, Jonathan A. Nowak, Brian M. Wolpin, Andrew J. Aguirre

Germline genetic analysis of KRAS WT versus KRAS mutant pancreatic cancer

Funding

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Lustgarten Foundation (The Lustgarten Foundation)

Doris Duke Charitable Foundation (DDCF)

History

ARTICLE ABSTRACT

Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multigene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the MAPK pathway, including BRAF mutations and in-frame deletions and receptor tyrosine kinase fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers, such as GNAS, MYC, PIK3CA, and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1 fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (median age: 62.6 vs. 65.7 years; P = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.

Usage metrics

    Clinical Cancer Research

    Categories

    Keywords

    cancer

    Licence

    CC BY

    Exports